A new FDA-approved assay known as the Prostate Health Index (PHI) has the potential to improve the detection of prostate cancer (PCa). The PHI is derived from 3 forms of the well-known prostate specific antigen (PSA) screening test including total PSA, percent-free PSA, and [-2]proPSA., This assay has shown promise in detecting advanced prostate cancer in European, Asian and US populations, but its effectiveness is relatively unknown in the African American population. African American (AA) men show higher rates of prostate cancer diagnoses and death from prostate cancer. Significantly, AAs have different ranges of PSA and our preliminary data indicate West African ancestry influences the odds of PCa in AA men. We aim to validate the safety and effectiveness of the PHI for AAs. Therefore, we will validate and compare the effectiveness of PHI in 300 AA men compared to 100 European American men recruited from outpatient urology clinics. We also will calibrate PHI for AAs and compare the effectiveness of the assay for AAs of high and low genetic West African ancestry. If the test performs well, we can help AA men avoid up to 27% of unnecessary prostate biopsies and better identify aggressive PCa early to reduce PCa disparities.
|Effective start/end date||11/1/16 → 11/1/20|
- V Foundation for Cancer Research (T2016-005// 09/29/2016)